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Introduction {#sec009}
============

The HIV-1 epidemic amongst men who have sex with men (MSM) is resurgent in many Western countries \[[@pmed.1001898.ref001]--[@pmed.1001898.ref005]\]. This may seem paradoxical, as HIV-positive men are being diagnosed at an increasingly earlier stage of HIV infection, and, since 1996, most diagnosed men take effective combination antiretroviral therapy (cART). Not only does successful therapy halt disease progression \[[@pmed.1001898.ref006]\], but successful suppression of virus replication also reduces the risk of transmitting HIV \[[@pmed.1001898.ref007],[@pmed.1001898.ref008]\]. With the introduction of cART, however, there has been an increase in unprotected sex in many countries. For the Netherlands, this was first demonstrated using a mathematical model that included disease progression to analyze national data from the ATHENA cohort on HIV and AIDS diagnoses and treatment success and failure \[[@pmed.1001898.ref001],[@pmed.1001898.ref002]\]. These findings were later confirmed by analysis of behavioral data from the Amsterdam Cohort Studies, which found that sexual risk behavior increased in a manner similar to model predictions \[[@pmed.1001898.ref009],[@pmed.1001898.ref010]\]. The resulting reproduction number for the epidemic amongst MSM was estimated to be around the epidemic threshold of one \[[@pmed.1001898.ref002]\]. In the period 2007--2010, 2,928 new HIV diagnoses were registered amongst MSM in the Netherlands, very similar to earlier predictions assuming no reductions in risk behavior \[[@pmed.1001898.ref002]\].

In the current study, we aimed to gain more insight into the transmission clusters that constitute this mainly HIV-1 subtype B epidemic amongst MSM over time \[[@pmed.1001898.ref011]\]. Similarly to an earlier Swiss study, we used phylogenetic analysis of extensive HIV-1 subtype B *polymerase* (*pol*) sequence data to identify large transmission clusters \[[@pmed.1001898.ref012]\]. The authors of the Swiss study subsequently estimated a reproduction number for each sub-epidemic directly from the sequence data \[[@pmed.1001898.ref013],[@pmed.1001898.ref014]\]. Here, we also analyze the viral transmission dynamics over time within the different clusters. However, we applied a mathematical model to the estimated incidence of diagnoses within each cluster, using the distribution of time between diagnoses of index cases and secondary cases derived from a previous study \[[@pmed.1001898.ref002],[@pmed.1001898.ref015]\]. Our analysis estimates the time-varying reproduction numbers of the large MSM-majority clusters that together drive the overall dynamics of the epidemic. This will clarify the extent to which the resurgent epidemic is the result of newly introduced strains or of growth of already circulating strains.

Methods {#sec010}
=======

The methods used in this study, along with the underlying assumptions, are summarized in [Fig 1](#pmed.1001898.g001){ref-type="fig"} and explained in detail below and in [S1 Text](#pmed.1001898.s013){ref-type="supplementary-material"}.

![Flow diagram describing the methods and underlying assumptions.](pmed.1001898.g001){#pmed.1001898.g001}

Patient Cohort {#sec011}
--------------

The ATHENA national observational HIV cohort includes anonymized data from all HIV-infected patients followed longitudinally in the 27 HIV treatment centers, in the Netherlands since 1 January 1996 and in the St. Elisabeth Hospital in Willemstad, Curaçao, since 1 January 2005, except 1.5% who opt out \[[@pmed.1001898.ref016]\]. Patients who were diagnosed between 1981 and 1995 were included in the cohort if they were still alive in 1 January 1996 \[[@pmed.1001898.ref002]\]. Demographic data were collected at entry in the cohort, including self-reported most likely risk group of infection, and most likely country of infection. Population-based nucleotide HIV-1 partial *pol* gene sequences were obtained as part of the screening for resistance to antiretroviral drugs, either before start of cART or at the time of virological failure, sometimes retrospectively, as described in detail previously \[[@pmed.1001898.ref011],[@pmed.1001898.ref017]\]. Subtype B sequences were identified by phylogenetic analysis using reference sequences from the Los Alamos HIV Sequence Database \[[@pmed.1001898.ref018]\]. As of 1 November 2011, the ATHENA cohort included 19,095 HIV-1-infected patients, of whom 7,589 (40%) had at least one sequence; 5,852 (77%) patients were infected with a subtype B strain.

At initiation, the ATHENA observational cohort was approved by the institutional review boards of all participating centers. It has subsequently become an integral part of HIV care and includes anonymized data and stored plasma samples from HIV-infected patients living in the Netherlands and receiving care in one of the designated HIV treatment centers. Patients can opt out after being informed by their treating physician of the purpose of collection of data and samples. Data from patients who opt out are not included in the ATHENA database. Anonymized data may be used for scientific purposes without further review. Patients are informed that if there are future requests for use of stored plasma samples for scientific research, they will be asked for prior consent by their treating HIV physician. Data are anonymized before being provided to investigators. For the purpose of our analysis, only existing data have been used, and therefore no additional review or consent has been necessary.

Recent HIV-1 Infections {#sec012}
-----------------------

Recent HIV-1 infections were defined as infections with either (i) a seroconversion interval of 18 mo or less between the last negative and the first positive HIV-1 serology test or (ii) a diagnosis of primary HIV-1 infection defined as detectable HIV-1 RNA in plasma, detectable serum p24 antigen in plasma, or both, combined with either a negative HIV-1 antibody test or a positive HIV-1 antibody test with a negative or indeterminate HIV-1 Western blot.

Patient Sequences in a Phylogenetic Context {#sec013}
-------------------------------------------

A phylogenetic context for the HIV sequences in our patient cohort was provided by sequences that were selected from the Los Alamos HIV Sequence Database \[[@pmed.1001898.ref018]\]. As of 15 March 2013, there were 56,643 subtype B sequences, one per patient, of minimal length 500, with a known country of sampling that was not the Netherlands. Sixteen sequences from Suriname were added from a previous study \[[@pmed.1001898.ref019]\]. For each of the 5,852 subtype B sequences in our dataset, the ten most similar sequences were identified by BLAST 2.2.22+ \[[@pmed.1001898.ref020]\]. In total, 2,468 unique sequences were added to the study.

Sequence Alignment {#sec014}
------------------

A total of 8,320 unique sequences were aligned using Clustal Omega 1.1.0 \[[@pmed.1001898.ref021]\] and manually checked and adjusted. Gblocks 0.91b was used to define the optimal sequence length of consistently aligned positions at 1,254 nucleotides \[[@pmed.1001898.ref022]\]. Major resistance-conferring sites at the amino acid positions described by the International AIDS Society--USA were excluded for phylogenetic analysis, including alternative substitutions at position 215 and two insertions \[[@pmed.1001898.ref023]\], resulting in an alignment length of 1,137 nucleotides.

Transmission Clusters {#sec015}
---------------------

A phylogenetic tree was built in FastTree 2.1.3 using a general time-reversible(GTR) model \[[@pmed.1001898.ref024]\]. PhyloPart 2.0 was used to define transmission clusters as those clusters of sequences with a local support value ≥ 0.9 based on 1,000 resamples and for which the median value of all pairwise patristic distances of the sub-tree was below the fifth percentile threshold of the distribution of all pairwise distances of the whole tree \[[@pmed.1001898.ref025]\], which corresponded to 0.068 mutations per site. We considered only large national transmission clusters with sequences from at least ten patients from within the ATHENA cohort \[[@pmed.1001898.ref012]\]. The median of the median values of all pairwise distances per large cluster was 0.042 (interquartile range \[IQR\] 0.030--0.057) mutations per site. The duration of a large cluster was defined as the time between the earliest and latest date of diagnosis within the cluster. As a sensitivity analysis, comparisons for three different cluster definitions were made: a "looser" cluster definition, with a local support value ≥ 0.8 and with a median value of all pairwise distances under the tenth percentile threshold, a "more stringent" cluster definition, with a local support value ≥ 0.95 and with a median value of all pairwise distances under the 2.5th percentile threshold, and a third cluster definition, with a local support value ≥ 0.9 and a single linkage distance threshold of 0.042 mutations/site.

Bayesian Time-Scaled Phylogenetic Analysis {#sec016}
------------------------------------------

We applied a Bayesian Markov chain Monte Carlo (MCMC) method as implemented in BEAST 1.7.5 for phylogenetic analysis of time-stamped sequence data to calculate the time of the most recent common ancestor (MRCA) of each large cluster. This value would indicate the time point since when each cluster has been circulating in the Netherlands, and simultaneously we confirmed the selected clusters by a different phylogenetic method. This was done by grouping clusters together in batches of approximately 200 sequences. Sequences from the Los Alamos HIV Sequence Database were included when the national cluster included ≥5 time-stamped sequences obtained in another country \[[@pmed.1001898.ref026]\]. We used the uncorrelated log-normal relaxed molecular clock with a discretized gamma-distributed general time-reversible substitution model and the Bayesian skyride coalescent model \[[@pmed.1001898.ref027],[@pmed.1001898.ref028]\]. Analyses of 200 million MCMC generations were performed, and evolutionary parameters were sampled every 20,000 generations to retrieve a distribution of posterior trees. After removing 10% of the initial output for burn-in, convergence of the MCMC output with effective sample size above 200 was inspected and confirmed in Tracer \[[@pmed.1001898.ref029]\]. Maximum clade credibility (MCC) trees keeping the heights of the target tree were obtained using TreeAnnotator 1.8.0 after discarding 10% of the posterior trees as burn-in and were visualized using FigTree 1.4.2 \[[@pmed.1001898.ref029]\]. Node ages and correspondent 95% highest posterior density (HPD) intervals were taken as the time of the MRCA and corresponding uncertainty estimates.

Estimation of the Time-Varying Case Reproduction Number within Transmission Clusters {#sec017}
------------------------------------------------------------------------------------

We analyzed HIV-1 transmission dynamics within each of the large transmission clusters containing a majority of MSM. For each cluster, we estimated the case reproduction number for each year *t*, *R* ~*t*~, defined as the average number of secondary cases infected by an index case diagnosed in year *t*. We used an extension of the method introduced by Wallinga and Teunis \[[@pmed.1001898.ref015]\], which allows estimation of *R* ~*t*~ based on the incidence of diagnosis time series and what we call the diagnosis interval distribution, i.e., the distribution of the time from diagnosis of an index case to diagnosis of a secondary case.

We extended the Wallinga and Teunis method to allow the diagnosis interval to vary according to the time of diagnosis of the index case, and to allow for the possibility that the diagnosis interval can be negative, because it is possible that individuals may have been infected by index cases who had not yet been diagnosed. The likelihood that case *i* has been infected by case *j* is decomposed into the product of the likelihood that the index case of *i* has been diagnosed and the relative likelihood that if the index case of *i* has been diagnosed, it is a particular individual *j*. The relative likelihood that case *i* has been infected by case *j* (rather than by another case diagnosed up to year *T*, here *T* = 2010) is given by $$p_{ij}^{*} = \frac{w_{t_{j}}(t_{i} - t_{j})}{\sum\limits_{k,k \neq i}{w_{t_{k}}(t_{i} - t_{k})}}$$ where *w* ~*t*~(.) denotes the distribution of the diagnosis interval for index cases diagnosed in year *t*.

The likelihood that case *i* has been infected by a case observed up to year *T* can be approximated by $$q_{i} = \frac{\sum\limits_{t = 0}^{T}{w_{t}(t_{i} - t)}}{\sum\limits_{t = 0}^{+ \infty}{w_{t}(t_{i} - t)}}$$ assuming that the incidence of diagnosed cases is constant over time (see [S1 Text](#pmed.1001898.s013){ref-type="supplementary-material"}). Additionally assuming that the diagnosis interval distribution remains unchanged after *T*, this ratio simplifies to $$q_{i} = \frac{\sum\limits_{t = 0}^{T}{w_{t}(t_{i} - t)}}{{\sum\limits_{t = 0}^{T}{w_{t}(t_{i} - t)}} + {\sum\limits_{t = T + 1}^{T + S}{w_{T}(t_{i} - t)}}}$$ where *S \>* 0 is the maximum possible negative diagnosis interval, such that for all *u \< −S* and *w* ~*T*~(*u*) *=* 0, the total likelihood that a diagnosed case *i* has been infected by case *j* (rather than by another case, diagnosed or not) is given by $$p_{ij} = p_{ij}^{*} \times q_{i} = \frac{w_{t_{j}}(t_{i} - t_{j})}{\sum\limits_{k,k \neq i}{w_{t_{k}}(t_{i} - t_{k})}} \times \frac{\sum\limits_{t = 0}^{T}{w_{t}(t_{i} - t)}}{{\sum\limits_{t = 0}^{T}{w_{t}(t_{i} - t)}} + {\sum\limits_{t = T + 1}^{T + S}{w_{T}(t_{i} - t)}}}.$$

Note that the derivation of *q* ~*i*~ assumes a constant incidence over time. Analyses presented in [S1 Text](#pmed.1001898.s013){ref-type="supplementary-material"} show how *q* ~*i*~ is modified when this assumption does not hold, and these analyses indicate that the resulting estimates of the reproduction number show consistent temporal trends regardless of the validity of this assumption, although the actual values may vary ([S2](#pmed.1001898.s002){ref-type="supplementary-material"} and [S3](#pmed.1001898.s003){ref-type="supplementary-material"} Figs).

The time-varying diagnosis interval *w* ~*t*~(.) was obtained by numerically simulating a compartmental HIV transmission model previously fitted to HIV and AIDS diagnosis data on MSM in the Netherlands, where it is assumed no transmission occurs when individuals are on treatment (see [S1 Text](#pmed.1001898.s013){ref-type="supplementary-material"}) \[[@pmed.1001898.ref002]\]. This mathematical model was used to estimate the time-varying diagnosis interval for the whole HIV epidemic amongst MSM, and not to directly fit to cluster dynamics (see [S1 Fig](#pmed.1001898.s001){ref-type="supplementary-material"}).

We further extended the Wallinga and Teunis method to incorporate uncertainty in the number of individuals diagnosed in a certain year *t*, *D* ~*t*~. The ATHENA cohort records the number *S* ~*t*~ of individuals diagnosed in year *t* who survived until 1996 and for whom a *pol* sequence was available. Therefore, we assumed that *D* ~*t*~ = *X* ~*t*~ + *S* ~*t*~, with *X* ~*t*~ ∼ Negbin(*S* ~*t*~, 1−φ~*t*~×π~*t*~), where φ~*t*~ is the probability that an individual diagnosed in year *t* survives until 1996 (taken from \[[@pmed.1001898.ref002]\]) and π~*t*~ is the probability that the virus is sequenced (taken from the ATHENA records) given survival up to 1996.

To estimate *R* ~*t*~ for each cluster, we first sampled *n =* 50 realizations of *D* ~*t*~ from this negative binomial distribution. For each of these, we then sampled 50 possible transmission chains (for each transmission chain, the index case of each secondary case *i* is sampled according to a multinomial distribution with probabilities *p* ~*ij*~), leading to a total of 2,500 likely transmission chains. For each chain, we counted the number of secondary cases corresponding to each case, and averaged over index cases diagnosed in the same year to get one *R* ~*t*~ trajectory over time. We pooled the 2,500 trajectories and used their mean and 2.5--97.5 quantiles as the point estimate and 95% confidence interval of *R* ~*t*~. Before pooling, each *R* ~*t*~ trajectory was corrected for right censoring to account for the fact that some of the secondary cases of index cases diagnosed in year *t* may not have been diagnosed yet, which may bias downwards the estimates of *R* ~*t*~, with a stronger effect in recent years. To correct for this effect, *R* ~*t*~ was divided by ${\sum\limits_{u = - S}^{2010 - t}w_{t}}(u)$, which represents the expected proportion of secondary cases of index cases diagnosed in year *t* who should be diagnosed in or before 2010, should overall transmission rates remain constant. Note that although this correction assumes that overall transmission rates will remain constant in the future, it still allows for heterogeneity in the times at which secondary cases appear relative to a given index case. We performed a sensitivity analysis to check that this right censoring correction was not introducing a systematic bias in the recent estimates of *R* ~*t*~ (see [S4 Fig](#pmed.1001898.s004){ref-type="supplementary-material"}).

Results {#sec018}
=======

Study Population and Phylogenetic Tree {#sec019}
--------------------------------------

Characteristics of the ATHENA patients are shown in [Table 1](#pmed.1001898.t001){ref-type="table"}. Of the 5,852 patients with a HIV-1 subtype B *pol* sequence in this study, 219 (4%) were registered in the cohort in Curaçao and 5,644 were registered in the Netherlands, of whom 4,288 (73%) reported being MSM, 207 (4%) reported being persons who inject drugs (PWID), and 849 (15%) reported being infected via heterosexual contact. Of HIV-positive MSM registered in the Netherlands and diagnosed before 1 January 1996, 35% (781/2,218) have a *pol* sequence included, versus 43% (3,507/8,247) of those diagnosed since 1 January 1996. Overall, 48% of MSM registered in the cohort in the Netherlands are treated in the capital city, Amsterdam, and account for 51% of the sequences in this study; 25% of MSM are treated in the other big cities in the western part of the country and account for 27% of the sequences. [S7 Fig](#pmed.1001898.s007){ref-type="supplementary-material"} shows the phylogenetic tree of a total of 8,320 unique *pol* sequences, including sequences obtained from the Los Alamos HIV Sequence Database.

10.1371/journal.pmed.1001898.t001

###### Patient baseline information.

![](pmed.1001898.t001){#pmed.1001898.t001g}

  Characteristic                                                  All HIV-1-Infected Patients         Patients with HIV-1 Non-B Subtype   Patients with HIV-1 Subtype B                                                                                                         
  --------------------------------------------------------------- ----------------------------------- ----------------------------------- ---------------------------------- ---------------------------------- ------------------------------- ------------------------------- --------------------------------
                                                                                                                                          **All**                            **MSM in the Netherlands**         **PWID in the Netherlands**     **HT in the Netherlands**       **Patients in Curaçao**
  ***n***                                                         19,095                              1,737                               5,852                              4,288                              207                             849                             219
  **Self-reported risk group of infection, *n* (percent)**                                                                                                                                                                                                                       
  MSM                                                             10,465 (55%)                        249 (14%)                           4,340 (74%)                        4,288                              ---                             ---                             52 (24%)
  HT                                                              6,258 (33%)                         1,228 (71%)                         996 (17%)                          ---                                ---                             849                             147 (67%)
  HT--male                                                        2,760                               488 (28%)                           526 (9%)                           ---                                ---                             447                             79 (36%)
  HT--female                                                      3,498                               740 (43%)                           470 (8%)                           ---                                ---                             402                             68 (31%)
  PWID                                                            736                                 22                                  207 (4%)                           ---                                207                             ---                             0
  Other and unknown                                               1,636                               238                                 309 (5%)                           ---                                ---                             ---                             20 (9%)
  **Age at diagnosis (years), median (IQR)**                      36 (IQR 29--43)                     32 (IQR 26--40)                     37 (IQR 30--44)                    37 (IQR 30--43)                    32 (IQR 27--39)                 34 (IQR 28--44)                 38 (IQR 29--46)
  **CD4 cell count at diagnosis (cells/μl), median (IQR)**        328 (IQR 130--530) (*n =* 13,308)   284 (IQR 110--480) (*n* = 1,350)    370 (IQR 186--560) (*n =* 4,335)   390 (IQR 210--570) (*n =* 3,302)   430 (IQR 190--670) (*n =* 83)   291 (IQR 80--511) (*n =* 656)   307 (IQR 101--449) (*n =* 105)
  **Year of diagnosis, median (IQR)**                             2002 (IQR 1997--2007)               2004 (IQR 2001--2007)               2004 (IQR 1997--2007)              2005 (IQR 1998--2008)              1994 (IQR 1990--1997)           2004 (IQR 1999--2007)           2002 (IQR 1998--2005)
  **Year of diagnosis, range**                                    1980--2011                          1981--2010                          1981--2010                         1981--2010                         1982--2010                      1985--2010                      1984--2010
  **Year sample sequenced, median (IQR)**                         ---                                 2006 (IQR 2003--2008)               2006 (IQR 2003--2008)              2006 (IQR 2003--2008)              2002 (IQR 1997--2005)           2006 (IQR 2003--2008)           2005 (IQR 2004--2009)
  **Year sample sequenced, range**                                ---                                 1991--2011                          1986--2011                         1986--2011                         1987--2010                      1996--2011                      1999--2011
  **Percent resistant mutations to any drug (PI, NNRTI, NRTI)**                                                                                                                                                                                                                 
  All patients                                                    ---                                 ---                                 30% (10%, 12%, 24%)                28% (9%, 11%, 23%)                 41% (13%, 15%, 37%)             32% (10%, 16%, 26%)             33% (15%, 10%, 29%)
  Treatment-naive patients                                        ---                                 ---                                 12% (2%, 5%, 7%) (*n =* 4,051)     12% (2%, 4%, 7%) (*n =* 3,161)     8% (2%, 3%, 2%) (*n =* 86)      11% (2%, 6%, 5%) (*n =* 546)    4% (1%, 1%, 3%) (*n =* 91)
  Patients with recent infection                                  ---                                 ---                                 12% (2%, 4%, 7%) (*n =* 1,265)     12% (2%, 4%, 7%) (*n =* 1,117)     10% (0%, 5%, 5%) (*n =* 40)     13% (3%, 4%, 6%) (*n =* 71)     0% (*n =* 6)
  **Region of origin, *n* (percent)**                                                                                                                                                                                                                                            
  Netherlands                                                     10,377 (54%)                        442 (25%)                           3,914 (67%)                        3,168 (74%)                        119 (57%)                       436 (51%)                       6 (3%)
  Former Dutch Antilles                                           1,236 (6%)                          16 (1%)                             366 (6%)                           105                                2 (1%)                          79 (9%)                         166 (76%)
  Suriname                                                        805 (4%)                            22 (1%)                             313 (5%)                           125 (3%)                           4 (2%)                          159 (19%)                       3 (1%)
  Latin America                                                   652 (3%)                            17 (1%)                             274 (5%)                           179 (4%)                           \-                              43 (5%)                         42 (19%)
  Western Europe                                                  1,228 (6%)                          36 (2%)                             400 (7%)                           313 (7%)                           32 (15%)                        37 (4%)                         ---
  Central Europe                                                  335 (2%)                            15 (1%)                             118 (2%)                           73 (2%)                            7 (3%)                          27 (3%)                         ---
  Eastern Europe                                                  114 (1%)                            21 (1%)                             31                                 23                                 1                               5                               ---
  North America                                                   264 (1%)                            3                                   94                                 79                                 4 (2%)                          2                               ---
  North Africa and Middle East                                    235 (1%)                            13 (1%)                             74                                 31                                 7 (3%)                          3                               ---
  Oceania                                                         66                                  7                                   19                                 18                                 ---                             ---                             ---
  Sub-Saharan Africa                                              3,040 (16%)                         1,063 (61%)                         55                                 36                                 1                               16 (2%)                         ---
  South and Southeast Asia                                        590 (3%)                            76 (4%)                             120                                95                                 4                               17 (2%)                         ---
  Australia                                                       37                                  2                                   10                                 10                                 ---                             ---                             ---
  Unknown                                                         139                                 3                                   82 (1%)                            51 (1%)                            26 (12%)                        3                               2
  **Self-reported country of infection, *n* (percent)**                                                                                                                                                                                                                          
  Netherlands                                                     10,223 (70%)                        398 (33%)                           3,918 (86%)                        3,118 (91%)                        141 (88%)                       507 (79%)                       8 (6%)
  Former Dutch Antilles                                           537 (4%)                            4                                   170 (4%)                           17                                 1                               36 (6%)                         110 (83%)
  US                                                              179 (1%)                            1                                   60 (1%)                            51 (1%)                            1                               2                               ---
  Suriname                                                        146 (1%)                            1                                   40 (1%)                            7                                  ---                             27 (4%)                         ---
  Other                                                           3,547 (24%)                         804 (67%)                           343 (8%)                           223 (7%)                           17 (11                          66 (10%)                        14 (11%)
  Unknown                                                         4,463                               529                                 1,321                              872                                47                              211                             87
  **Region of hospital, *n* (percent)**                                                                                                                                                                                                                                          
  Curaçao                                                         700 (4%)                            5                                   219 (4%)                           ---                                ---                             ---                             219
  Amsterdam                                                       7,424 (39%)                         712 (41%)                           2,879 (51%)                        2,201 (51%)                        124 (60%)                       414 (49%)                       ---
  **In a cluster with ≥10 ATHENA sequences**                      ---                                 ---                                 3,716 (52%)                        2,196 (51%)                        153 (74%)                       474 (56%)                       103 (47%)

HT, heterosexual transmission; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protein inhibitor.

Transmission Clusters {#sec020}
---------------------

From the total phylogenetic tree, 106 large transmission clusters were identified that included HIV *pol* sequences from ≥10 patients from the ATHENA cohort, illustrated in [Fig 2](#pmed.1001898.g002){ref-type="fig"} stratified by majority risk group of infection and cluster duration. The 106 clusters included 52% (3,061) of sequences from 5,852 ATHENA patients and 652 sequences obtained from the Los Alamos HIV Sequence Database. Only 15 of the 106 clusters were not MSM-majority clusters (≥50% MSM). Of these, 11 clusters were dominated by heterosexually infected individuals of Suriname or Antillean origin, one was dominated by PWID of Polish origin, and two were mixed heterosexual and MSM clusters of mostly Dutch origin. The largest cluster included sequences from 136 (42%) PWID---hence, from 66% of all PWID with a sequence in this study---and also included sequences from 122 (37%) heterosexually infected individuals and from 24 (7%) MSM. It also included 200 HIV *pol* sequences from the Los Alamos sequences. [Fig 3](#pmed.1001898.g003){ref-type="fig"} illustrates all clusters by region of origin. See [S1 Trees](#pmed.1001898.s014){ref-type="supplementary-material"} for timed trees of all clusters and [S1 Text](#pmed.1001898.s013){ref-type="supplementary-material"} for more detailed information on the largest PWID cluster and the transmission clusters circulating on Curaçao.

![Large transmission clusters over time: risk group of infection.\
The picture illustrates the distribution of 106 large transmission clusters, where every horizontal line of dots represents one cluster, and each dot represents a single patient in the cluster by the year of diagnosis. The dots in a cluster represent in total 52% (3,061) of 5,852 ATHENA patients with a HIV-1 subtype B *pol* sequence in this study. The clusters are ordered by majority risk group and by the number of years between the first and last patient identified within each particular cluster. The color of each dot represents the self-reported risk group of infection. X's indicate the estimated time of the MRCA, in orange for Curaçao. Some discrepancies may arise as the earliest cases sometimes are included with a sequence many years after their year of diagnosis. On the right-hand side the estimated mean reproduction number over the last 5 y is indicated. At the bottom of the figure, patients are represented who could not be identified as belonging to a cluster. The group above this one shows those patients who belonged to clusters in the phylogenetic tree with fewer than 10 ATHENA sequences included, which were not regarded as large clusters according to our definition. [S8 Fig](#pmed.1001898.s008){ref-type="supplementary-material"} shows the same figure with also these smaller clusters stratified by duration. HT, heterosexual transmission.](pmed.1001898.g002){#pmed.1001898.g002}

![Large transmission clusters over time: region of origin.\
As in [Fig 2](#pmed.1001898.g002){ref-type="fig"}, but here the color of each dot represents the region of origin. In large MSM-majority clusters 79% (1,673) of MSM were of Dutch origin. HT, heterosexual transmission.](pmed.1001898.g003){#pmed.1001898.g003}

MSM-Majority Clusters {#sec021}
---------------------

Fifty percent (2,128) of the 4,288 MSM registered in the ATHENA cohort in the Netherlands with a sequence in this study were in 91 large MSM-majority (≥50%) transmission clusters including at least ≥10 patients from the ATHENA cohort. A further 28% (1,192) were in 417 small clusters containing 2--9 ATHENA sequences; 21% (900) were singletons, of whom 132 clustered solely with foreign sequences; and only 68 were in nine of the non-MSM-dominated clusters ([Fig 4](#pmed.1001898.g004){ref-type="fig"}). The median number of MSM registered in the cohort in the Netherlands per large cluster was 16 (IQR 11--27, range 5--121).

![Diagnosis and growth of transmission clusters over time.\
Cluster types within the phylogenetic tree are defined as follows. Singletons (in blue) are clusters of size 1, or cases whose sequence solely clustered with sequences from the Los Alamos HIV Sequence Database. Small clusters (in green) comprise sequences from 2--9 ATHENA patients. Large clusters comprise sequences from ten or more patients in the ATHENA cohort. Amongst those, non-MSM-dominant clusters (in brown) contain a majority of sequences from non-MSM patients, whilst MSM-majority clusters contain a majority of sequences from MSM patients. Among large MSM-majority clusters, pre-1996 clusters (in dark orange) are defined as those in which the first diagnosed patient in the cluster was diagnosed before 1996, and post-1996 clusters are defined as those in which all patients in the cluster were diagnosed in or after 1996. Large MSM-majority post-1996 clusters are stratified as "time of MRCA pre-1996" (in light orange) when the estimated time of the MRCA is before 1996, and "time of MRCA post-1996" (in purple) when the estimated time of the MRCA is in or after 1996. (A) Number of MSM registered in the ATHENA cohort in the Netherlands with a sequence in this study by year of diagnosis and by cluster type. (B) Number of clusters of each type by year of first diagnosed case in each cluster.](pmed.1001898.g004){#pmed.1001898.g004}

At least 59% (54) of the 91 large MSM-majority clusters were already circulating before 1996 ([Fig 4](#pmed.1001898.g004){ref-type="fig"}). Most clusters were confirmed in the BEAST analysis. Figs [2](#pmed.1001898.g002){ref-type="fig"}, [3](#pmed.1001898.g003){ref-type="fig"}, and [5](#pmed.1001898.g005){ref-type="fig"} show the estimated time of the MRCA of all clusters, and the 95% HPD intervals are in [S2 Table](#pmed.1001898.s012){ref-type="supplementary-material"}. These estimations indicate that 23 (95% HPD interval 8--33) of the clusters identified in or after 1996 (57%) might have started off before 1996, but also that 14 (95% HPD interval 4--29) of these clusters started off more recently ([Fig 4](#pmed.1001898.g004){ref-type="fig"}).

![Large transmission clusters over time: recent infections.\
As in [Fig 2](#pmed.1001898.g002){ref-type="fig"}, but here red dots represent patients with a documented recent infection. HT, heterosexual transmission.](pmed.1001898.g005){#pmed.1001898.g005}

Of 3,460 MSM with a sequence in this study who were registered in the ATHENA cohort in the Netherlands and diagnosed after 1996, 1,226 (35%) were infected within 54 transmission clusters circulating before 1996, and 20% (700) within 37 large clusters identified in or after 1996; of the latter, 429 (95% HPD interval 272--621) were in clusters with a time of the MRCA before 1996. Thus, in total, 48% (95% HPD interval 43%--53%) of these men diagnosed in or after 1996 were infected within a cluster that started circulating in the Netherlands before 1996. The proportion of these men diagnosed in the 54 clusters identified before 1996 increased over time to 42% in 2010; the proportion in either these clusters or clusters identified since 1996 but with a time of the MRCA before 1996 increased to 55% (95% HPD interval 53%--62%). Those diagnosed within any of the large clusters increased to 68% ([Fig 4](#pmed.1001898.g004){ref-type="fig"}).

### Recent infections {#sec022}

Of the 54 pre-1996 clusters, 78% (40) included recent infections after 2000 ([Fig 5](#pmed.1001898.g005){ref-type="fig"}). Since 1996, a recent infection at diagnosis could be identified amongst 41% of MSM in large clusters, 31% of MSM in smaller clusters, and 22% of MSM singletons. Only three (6%) of the 54 pre-1996 clusters had no new diagnoses observed in the last 5 y of the study period, 2006--2010.

### Country of infection {#sec023}

Amongst 3,416 MSM registered in the ATHENA cohort in the Netherlands with a sequence in this study who reported a most likely country of infection, 4.3% of MSM in large clusters reported likely having been infected abroad, and likewise 8.1% (risk ratio \[RR\] = 1.9; 95% CI 1.4--2.6) in smaller clusters, 19.0% (RR = 4.5; 95% CI 3.4--5.9) of singletons, and 27.8% (RR = 6.5; 95% CI 4.4--9.7) of MSM clustering solely with one or more Los Alamos sequences. This indicates that singletons, besides being part of unidentified clusters of national transmission, often represent new introductions.

### Data versus theory {#sec024}

[Fig 4](#pmed.1001898.g004){ref-type="fig"} illustrates that only a small minority (7%) of all the observed phylogenetic MSM clusters (sum of singletons and small and large clusters) were established "large" transmission clusters including ten or more cases. This is broadly consistent with results from branching theory, which indicates that this proportion should be between 6% and 35% for a reproduction number between 0.8 and 1.2 (see [S1 Text](#pmed.1001898.s013){ref-type="supplementary-material"}). Theoretical results also show that this observed proportion is a good approximation for the proportion of introductions leading to sub-epidemics of ten cases or more, with little sensitivity to the proportion of cases whose virus was sequenced.

Estimation of the Case Reproduction Number within Large MSM-Majority Transmission Clusters {#sec025}
------------------------------------------------------------------------------------------

[Fig 6](#pmed.1001898.g006){ref-type="fig"} shows the estimated annual case reproduction number for all 91 large MSM-majority transmission clusters. With a reproduction number around one (the critical value that separates epidemic spread from contraction), clusters were self-sustaining over the whole study period. Reproduction numbers were strikingly consistent across clusters. A tendency towards higher numbers was visible over recent years, especially in the more recently introduced clusters (see [S6 Fig](#pmed.1001898.s006){ref-type="supplementary-material"}). Seventy-five percent (68) of the clusters had a mean reproduction number greater than one over the last 5 y ([Fig 2](#pmed.1001898.g002){ref-type="fig"}).

![Estimated case reproduction number over time for all MSM-majority transmission clusters of ≥10 cases.\
The solid lines show the mean *R* ~*t*~ estimate for each transmission cluster. The bold black line is the mean *R* ~*t*~ of all clusters, with the 95% confidence interval shown by the dotted lines. The shaded areas show the 95% confidence intervals for each transmission cluster: darker areas indicate overlapping intervals across different transmission clusters. Transmission clusters are shown in red if their first sequence appeared before 1991, in blue if their first sequence appeared between 1991 and 2000, and in green if their first diagnosed case appeared after 2000. The black horizontal dotted line represents the threshold value *R* ~*t*~ = 1. (A) Main analysis. (B) Sensitivity analysis for a looser cluster definition. (C) Sensitivity analysis for a more stringent cluster definition. (D) Sensitivity analysis for the clusters defined under a single linkage branch length threshold.](pmed.1001898.g006){#pmed.1001898.g006}

Sensitivity Analysis {#sec026}
--------------------

With the looser cluster definition, 105 large MSM-majority clusters were selected, containing 69% (2,977) of the HIV *pol* sequences from MSM registered in the ATHENA cohort in the Netherlands, and only 4% (183) of sequences were singletons. In this sensitivity analysis, 17% of all observed phylogentic MSM clusters (including the singletons) included ten or more cases. With the more stringent cluster definition, 67 clusters were identified, containing 39% (1,670) of the *pol* sequences from MSM registered in the cohort in the Netherlands. With clusters defined under the single linkage branch length threshold, 63 large MSM-majority clusters were selected, containing 69% (2,974) of the *pol* sequences from MSM registered in the cohort in the Netherlands. In this analysis also, only a small minority (5%) of all observed phylogentic MSM clusters included ten or more cases. The estimations of the case reproduction number for the large MSM-majority clusters in all three sensitivity analyses were similar to those in our main analysis ([Fig 6](#pmed.1001898.g006){ref-type="fig"}).

Age of MSM at Diagnosis {#sec027}
-----------------------

[Fig 7](#pmed.1001898.g007){ref-type="fig"} shows that the HIV epidemic is shifting from the initially infected generations of MSM towards younger generations. The mean age at diagnosis of MSM in our study has been increasing by 0.31 years per calendar year overall. However, this overall trend hides more complicated dynamics because within each of the 91 large MSM-majority clusters, the mean age at diagnosis has increased more rapidly, at a rate of 0.45 years/year, compared to the epidemic as a whole. On the other hand, new clusters have started with a lower initial mean age, which, across clusters, has increased at rate of only 0.28 years/year.

![Proportional contribution of new HIV-1 diagnoses amongst all MSM in the ATHENA cohort by decade of birth.](pmed.1001898.g007){#pmed.1001898.g007}

Discussion {#sec028}
==========

This study provides insight into the different transmission clusters that have contributed to the ongoing resurgent HIV epidemic amongst MSM in the Netherlands. We found that clusters that started spreading before the introduction of cART in 1996 still constitute the main source for new HIV-1 subtype B infections (\~55% in 2010). Calculations of the reproduction number separately for each cluster show that whilst the epidemic diminished at the population level during the 1990s \[[@pmed.1001898.ref001],[@pmed.1001898.ref002],[@pmed.1001898.ref010]\], most of these clusters continued spreading in a self-sustaining manner. There is little indication that any of the clusters will stop in the near future as most clusters contain recent infections and are rejuvenated by the inclusion of younger men, and many have a reproduction number greater than the epidemic threshold. While all clusters appear to be aging, new clusters appear to be of lower mean age; if anything, these "younger" clusters have higher epidemic potential than the "older" clusters. It is also conceptually interesting to see the whole HIV-1 subtype B epidemic disaggregated in a single figure (Figs [2](#pmed.1001898.g002){ref-type="fig"} and [3](#pmed.1001898.g003){ref-type="fig"}). This perspective illustrates the tight links between clusters on Curaçao with people from the same region living in the Netherlands \[[@pmed.1001898.ref019],[@pmed.1001898.ref030]--[@pmed.1001898.ref032]\]. It also shows that the largest transmission cluster, which is dominated by PWID, shows links to heterosexual transmission but is an almost entirely separate epidemic from that amongst MSM.

The median reproduction number of all large clusters together found in this study is consistent with our previous findings of the HIV epidemic amongst MSM in that it is around the epidemic threshold and increases in later years. However, our previous study reported the mean reproduction number aggregated over the whole epidemic, whilst our findings here are based on disaggregating the epidemic into its constituent sub-epidemics. We found that the resurgent epidemic is the result of existing transmission clusters, many of which have been spreading since the early epidemic, to which new transmission clusters are being added. There seems to be a high and continued rate of case importation, but with only a small minority of cases going on to establish new self-sustaining clusters ([Fig 5](#pmed.1001898.g005){ref-type="fig"}). This heterogeneity of outcomes is in line with expectations from epidemiological theory, as we also show in [S1 Text](#pmed.1001898.s013){ref-type="supplementary-material"}: self-sustaining sub-epidemics are hard to establish but, once initiated, are difficult to stop \[[@pmed.1001898.ref033]\]. The higher percentage of recent infections in large clusters versus small clusters and singletons could indicate an effect of partner tracing. Several studies indicated that a large part of onward transmission amongst MSM is during the early phase of infection \[[@pmed.1001898.ref011],[@pmed.1001898.ref034]--[@pmed.1001898.ref037]\]. And thus it is worrying that even though an increasing number of MSM with HIV are diagnosed early in infection, this does not seem to have stopped clusters from growing.

The clusters and findings were confirmed using different phylogenetic methods and cluster definitions. However, by phylogenetic methods alone and using only *pol* sequences of only a subset of patients, we were not able to fully identify all transmission chains. The focus in our study was on the large transmission clusters. The observation that sequences from patients diagnosed before 1996 were less often part of a large cluster could indicate that some initial clusters have stopped circulating and have gone unnoticed. It is also possible that, since the sample fraction was lower in early years, fewer individuals appear to cluster (due to missing links), even though they were in fact linked to larger transmission clusters via unknown intermediates.

Our estimates of the reproduction number are based on a number of assumptions, including that the distribution of the diagnosis interval (time from diagnosis of an index case to diagnosis of a secondary case) is similar across clusters and similar across the whole HIV-positive population in the Netherlands. These estimates also assume that the probability of having a sequence obtained and the probability of surviving until 1996 are similar across clusters. It should be noted that the reproduction numbers estimated in this study are effective reproduction numbers. Our findings might thus indicate local or temporal saturation effects in certain sexual networks. However, as prevalence of HIV amongst MSM ranges from 5% to 8% \[[@pmed.1001898.ref038]\], behavior change, not saturation, is expected to be the dominant driver of epidemic trends in this population. For a future study it would be interesting to compare findings, from real and simulated data, with recent studies that obtained reproduction numbers for large transmission clusters directly from sequence data \[[@pmed.1001898.ref013],[@pmed.1001898.ref014]\].

This study, combining phylogenetic methods with mathematical modeling to analyze extensive HIV-1 subtype B sequence data, provides new insight into how different transmission networks together contribute to the resurgent HIV epidemic in the Netherlands. The analysis suggests that the epidemic amongst MSM is dispersed amongst a large number of self-sustaining or growing transmission clusters, many of which persisted throughout the 1990s, before increases in risk behavior became widespread. In particular, the relative homogeneity and consistency of reproduction number estimates for the different networks was unexpected. Our study highlights that many different sub-epidemics have independently persisted for decades, despite the widespread availability of treatment, steadily increasing rates of diagnosis, and increasing tendency for early treatment initiation. The fastest growing sub-epidemics are the newest ones, which also tend to be amongst the youngest men. Preventing further increases in rates of infection will require further developments in prevention services.

Supporting Information {#sec029}
======================

###### Distribution of the diagnosis interval stratified by year of diagnosis of the index case.

(PDF)

###### 

Click here for additional data file.

###### *q* ~*i*~ as a function of time in different scenarios regarding incidence growth over time.

The black line shows the scenario with constant incidence over time, which was considered in the main text.

(PDF)

###### 

Click here for additional data file.

###### Influence of assumptions underlying *q* ~*i*~ derivation on the estimates of yearly reproduction numbers *R* for the four largest transmission clusters.

(PDF)

###### 

Click here for additional data file.

###### Estimated case reproduction number over time for all MSM-majority transmission clusters with ≥10 cases diagnosed before 2000.

The solid lines show the mean *R* ~*t*~ estimates for each transmission cluster using the dataset truncated after 2000 (black lines) and using the full dataset (blue lines). The shaded areas show the 95% confidence intervals for each transmission cluster (black shading for the dataset truncated after 2000, blue shading for the full dataset). The red horizontal line represents the threshold value *R* ~*t*~ = 1.

(PDF)

###### 

Click here for additional data file.

###### Comparison of *R* ~*t*~ in different time periods.

(PDF)

###### 

Click here for additional data file.

###### Increasing *R* ~*t*~.

\(A\) Number of cases in the first 5 y of each cluster and overall sample fraction. (B) Rate of increase in the mean estimated *R* ~*t*~ over the first 5 y for each cluster.

(PDF)

###### 

Click here for additional data file.

###### Phylogenetic tree of a total of 8,320 HIV-1 subtype B *pol* sequences.

Branches corresponding to the 5,852 ATHENA patients are colored by self-reported risk group of infection. HT, heterosexual transmission.

(PDF)

###### 

Click here for additional data file.

###### Large transmission clusters over time.

As in [Fig 2A](#pmed.1001898.g002){ref-type="fig"}, but including the small clusters including 2--9 ATHENA sequences sorted by duration.

(PDF)

###### 

Click here for additional data file.

###### Timed tree of HIV-1 *pol* sequences from patients in the six largest clusters on Curaçao.

\(A\) Branches are colored according to region of residence. (B) Branches are colored according to the self-reported risk group of infection. The root of each cluster is indicated in bold. HT, heterosexual transmission.

(PDF)

###### 

Click here for additional data file.

###### Observed and expected proportion of singletons and small clusters.

Under the Poisson (left) and geometric (right) model. The top three rows show how these proportions change as a function of π, the proportion of cases with a sequence, for a mean number of offspring of *R* = 1, *R* = 0.9, and *R* = 1.1, respectively. The vertical red dotted lines indicate the observed proportion of cases with a sequence, π = 0.3 over the whole time period considered. The bottom row shows how the proportions of singletons and small clusters change as a function of *R*, the mean number of offspring, for a proportion of cases with a sequence of π = 0.3. In all plots, the black and grey curves show the expected and observed proportion of singletons, respectively, with dotted lines indicating confidence intervals around the observed proportion; the dark and light blue curves show the expected and observed proportion of small clusters (size 2--9), with dashed lines indicating confidence intervals around the observed proportion.

(PDF)

###### 

Click here for additional data file.

###### Phylogenetic trait association test on structuring within the largest HIV-1 subtype B transmission cluster in the Netherlands.

To test whether HIV-1 *pol* sequences in the last 1,000 posterior trees obtained by BEAST were structured more strongly by risk group for the ATHENA sequences and more strongly by country for the sequences from the Los Alamos HIV Sequence Database \[[@pmed.1001898.ref018]\] than expected by chance alone, a phylogenetic trait association analysis using Bayesian tip-association significance testing was performed \[[@pmed.1001898.ref039]\]. The maximum monophyletic clade (MC) size statistic was estimated for each trait, which provides an estimate of the mean cluster size of sequences sampled for each trait. Significant clustering is defined as critical (*p* \< 0.01), marginally significant (0.01 ≤ *p* ≤ 0.05), or not significant (*p* \> 0.05).

(PDF)

###### 

Click here for additional data file.

###### Time of the MRCA and 95% HPD intervals of the 91 large majority MSM phylogenetic clusters.

(XLS)

###### 

Click here for additional data file.

###### Supporting information on methods, sensitivity analysis, and results.

(PDF)

###### 

Click here for additional data file.

###### Timed trees of 91 MSM-majority clusters.

The first number of the branch name is the cluster name. Bars indicate the 95% HPD intervals of the node ages. In total, 380 of the Los Alamos sequences selected are included in the 91 large MSM-majority clusters. Twenty-six clusters have no Los Alamos sequences included. Nine clusters include ≥5 time-stamped sequences from a particular country (Foreign). Although some mixing is visible, these sequences form mainly separate clusters within the respective countries. Timed tree of the 15 other clusters (Other): four clusters with a majority of patients of Suriname origin, three clusters with a majority of patients of Antillean origin, two clusters of heterosexually infected individuals and MSM of mainly Dutch origin, one cluster with mainly PWID of Polish origin, the largest PWID cluster, and the six clusters on Curaçao with bars (two are also in MSM).

(ZIP)

###### 

Click here for additional data file.

The members of the ATHENA observational cohort are as follows. Asterisks denote site coordinating physicians.

**Clinical Centers. Academic Medical Center, University of Amsterdam, Amsterdam:** *HIV treating physicians*: J. M. Prins\*, T. W. Kuijpers, H. J. Scherpbier, J. T. M. van der Meer, F. W. M. N. Wit, M. H. Godfried, P. Reiss, T. van der Poll, F. J. B. Nellen, S. E. Geerlings, M. van Vugt, D. Pajkrt, J. C. Bos, W. J. Wiersinga, M. van der Valk, A. Goorhuis, J. W. Hovius. *HIV nurse consultants*: J. van Eden, A. Henderiks, A. M. H. van Hes, M. Mutschelknauss, H. E. Nobel, F. J. J. Pijnappel, A. M. Westerman. *HIV clinical virologists/chemists*: S. Jurriaans, N. K. T. Back, H. L. Zaaijer, B. Berkhout, M. T. E. Cornelissen, C. J. Schinkel, X. V. Thomas. **Admiraal De Ruyter Ziekenhuis, Goes:** *HIV treating physicians*: M. van den Berge, A. Stegeman. *HIV nurse consultants*: S. Baas, L. Hage de Looff. *HIV clinical virologists/chemists*: D. Versteeg. **Catharina Ziekenhuis, Eindhoven:** *HIV treating physicians*: M. J. H. Pronk\*, H. S. M. Ammerlaan. *HIV nurse consultants*: E. M. H. M. Korsten-Vorstermans, E. S. de Munnik. *HIV clinical virologists/chemists*: A. R. Jansz, J. Tjhie, M. C. A. Wegdam, B. Deiman, V. Scharnhorst. **Emma Kinderziekenhuis, Amsterdam:** *HIV nurse consultants*: A. van der Plas, A. M. Weijsenfeld. **Erasmus Medisch Centrum, Rotterdam:** *HIV treating physicians*: M. E. van der Ende\*, T. E. M. S. de Vries-Sluijs, E. C. M. van Gorp, C. A. M. Schurink, J. L. Nouwen, A. Verbon, B. J. A. Rijnders, H. I. Bax, R. J. Hassing, M. van der Feltz. *HIV nurse consultants*: N. Bassant, J. E. A. van Beek, M. Vriesde, L. M. van Zonneveld. *Data collection*: A. de Oude-Lubbers, H. J. van den Berg-Cameron, F. B. Bruinsma-Broekman, J. de Groot, M. de Zeeuw- de Man. *HIV clinical virologists/chemists*: M. Schutten, A. D. M. E. Osterhaus, C. A. B. Boucher. **Erasmus Medisch Centrum--Sophia, Rotterdam:** *HIV treating physicians*: G. J. A. Driessen, A. M. C. van Rossum. *HIV nurse consultants*: L. C. van der Knaap, E. Visser. **Flevoziekenhuis, Almere:** *HIV treating physicians*: J. Branger\*. *HIV nurse consultants/data collection*: C. J. H. M. Duijf-van de Ven. **HagaZiekenhuis, Den Haag:** *HIV treating physicians*: E. F. Schippers\*, C. van Nieuwkoop, R. W. Brimicombe. *HIV nurse consultants*: J. M. van IJperen. *Data collection*: G. van der Hut. *HIV clinical virologists/chemists*: P. F. H. Franck. **HIV Focus Centrum (DC Klinieken), Amsterdam:** *HIV treating physicians*: A. van Eeden\*. *HIV nurse consultants*: W. Brokking, M. Groot, L. J. M. Elsenburg. *HIV clinical virologists/chemists*: M. Damen, I. S. Kwa. **Isala Klinieken, Zwolle:** *HIV treating physicians*: P. H. P. Groeneveld\*, J. W. Bouwhuis. *HIV nurse consultants*: J. F. van den Berg, A. G. W. van Hulzen. *Data collection*: G. L. van der Bliek, P. C. J. Bor. *HIV clinical virologists/chemists*: P. Bloembergen, M. J. H. M. Wolfhagen, G. J. H. M. Ruijs. **Leids Universitair Medisch Centrum, Leiden:** *HIV treating physicians*: F. P. Kroon\*, S. M. Arend, M. G. J. de Boer, M. P. Bauer, H. Jolink, A. M. Vollaard. *HIV nurse consultants*: W. Dorama, N. van Holten. *HIV clinical virologists/chemists*: E. C. J. Claas, A. C. M. Kroes. **Maasstad Ziekenhuis, Rotterdam:** *HIV treating physicians*: J. G. den Hollander\*, K. Pogany. *HIV nurse consultants*: M. Kastelijns, J. V. Smit, E. Smit. *Data collection*: M. Bezemer, T. van Niekerk. *HIV clinical virologists/chemists*: O. Pontesilli. **Maastricht UMC+, Maastricht:** *HIV treating physicians*: S. H. Lowe\*, A. Oude Lashof, D. Posthouwer. *HIV nurse consultants*: R. P. Ackens, J. Schippers, R. Vergoossen. *Data collection*: B. Weijenberg Maes. *HIV clinical virologists/chemists*: P. H. M. Savelkoul, I. H. Loo. **Medisch Centrum Slotervaart, Amsterdam:** *HIV treating physicians*: J. W. Mulder, S. M. E. Vrouenraets, F. N. Lauw. *HIV nurse consultants*: M. C. van Broekhuizen, H. Paap, D. J. Vlasblom. *Data collection*: E. Oudmaijer Sanders. *HIV clinical virologists/chemists*: P. H. M. Smits, A. W. Rosingh. **Medisch Centrum Zuiderzee, Lelystad:** *HIV treating physicians*: S. Weijer\*, R. El Moussaoui. *HIV nurse consultant*: A. S. Bosma. **Medisch Centrum Alkmaar, Alkmaar:** *HIV treating physicians*: W. Kortmann\*, G. van Twillert\*, J. W. T. Cohen Stuart, B. M. W. Diederen. *HIV nurse consultants/data collection*: D. Pronk, F. A. van Truijen-Oud. *HIV clinical virologists/chemists*: W. A. van der Reijden, R. Jansen. **Medisch Centrum Haaglanden, Den Haag:** *HIV treating physicians*: E. M. S. Leyten\*, L. B. S. Gelinck. *HIV nurse consultants*: A. van Hartingsveld, C. Meerkerk, G. S. Wildenbeest. *HIV clinical virologists/chemists*: J. A. E. M. Mutsaers, C. L. Jansen. **Medisch Centrum Leeuwarden, Leeuwarden:** *HIV treating physicians*: M. G. A. van Vonderen\*, D. P. F. van Houte, L. M. Kampschreur. *HIV nurse consultants*: K. Dijkstra, S. Faber. *HIV clinical virologists/chemists*: J. Weel. **Medisch Spectrum Twente, Enschede:** *HIV treating physicians*: G. J. Kootstra\*, C. E. Delsing. *HIV nurse consultants*: M. van der Burg-van de Plas, H. Heins. *Data collection*: E. Lucas. **Onze Lieve Vrouwe Gasthuis, Amsterdam:** *HIV treating physicians*: K. Brinkman\*, P. H. J. Frissen, W. L. Blok, W. E. M. Schouten, G. E. L. van den Berk. *HIV nurse consultants*: C. J. Brouwer, G. F. Geerders, K. Hoeksema, M. J. Kleene, I. B. van der Meché, A. J. M. Toonen, S. Wijnands. *HIV clinical virologists/chemists*: M. L. van Ogtrop, R. Jansen. **Radboudumc, Nijmegen:** *HIV treating physicians*: P. P. Koopmans, M. Keuter, A. J. A. M. van der Ven, H. J. M. ter Hofstede, A. S. M. Dofferhoff, R. van Crevel. *HIV nurse consultants*: M. Albers, M. E. W. Bosch, K. J. T. Grintjes-Huisman, B. J. Zomer. *HIV clinical virologists/chemists*: F. F. Stelma. *HIV clinical pharmacology consultant*: D. Burger. **Rijnstate, Arnhem:** *HIV treating physicians*: C. Richter\*, J. P. van der Berg, E. H. Gisolf. *HIV nurse consultants*: G. ter Beest, P. H. M. van Bentum, N. Langebeek. *HIV clinical virologists/chemists*: R. Tiemessen, C. M. A. Swanink. **Sint Lucas Andreas Ziekenhuis, Amsterdam:** *HIV treating physicians*: J. Veenstra\*, K. D. Lettinga. *HIV nurse consultants*: M. Spelbrink, H. Sulman. *Data collection*: M. Spelbrink, E. Witte. *HIV clinical virologists/chemists*: M. Damen, P. G. H. Peerbooms. **Spaarne Gasthuis, Haarlem:** *HIV treating physicians*: S. F. L. van Lelyveld\*, R. Soetekouw. *HIV nurse consultants*: N. Hulshoff, L. M. M. van der Prijt, J. van der Swaluw. *Data collection*: N. Bermon. *HIV clinical virologists/chemists*: W. A. van der Reijden, R. Jansen, B. L. Herpers, D. Veenendaal. **Stichting Medisch Centrum Jan van Goyen, Amsterdam:** *HIV treating physicians*: D. W. M. Verhagen. *HIV nurse consultants*: J. Geilings. **St Elisabeth Ziekenhuis, Tilburg:** *HIV treating physicians*: M. E. E. van Kasteren\*, A. E. Brouwer. *HIV nurse consultants/data collection*: B. A. F. M. de Kruijf-van de Wiel, M. Kuipers, R. M. W. J. Santegoets, B. van der Ven. *HIV clinical virologists/chemists*: J. H. Marcelis, A. G. M. Buiting, P. J. Kabel. **Universitair Medisch Centrum Groningen, Groningen:** *HIV treating physicians*: W. F. W. Bierman\*, H. G. Sprenger, E. H. Scholvinck, S. van Assen, K. R. Wilting, Y. Stienstra. *HIV nurse consultants*: H. de Groot-de Jonge, P. A. van der Meulen, D. A. de Weerd. *HIV clinical virologists/chemists*: H. G. M. Niesters, A. Riezebos-Brilman, C. C. van Leer-Buter. **Universitair Medisch Centrum Utrecht, Utrecht:** *HIV treating physicians*: A. I. M. Hoepelman\*, M. M. E. Schneider, T. Mudrikova, P. M. Ellerbroek, J. J. Oosterheert, J. E. Arends, R. E. Barth, M. W. M. Wassenberg. *HIV nurse consultants*: D. H. M. van Elst-Laurijssen, E. E. B. van Oers-Hazelzet, J. Patist, S. Vervoort, *Data collection*: H. E. Nieuwenhuis, R. Frauenfelder. *HIV clinical virologists/chemists*: R. Schuurman, F. Verduyn-Lunel, A. M. J. Wensing. **VU Medisch Centrum, Amsterdam:** *HIV treating physicians*: E. J. G. Peters\*, M. A. van Agtmael, M. Bomers, J. de Vocht. *HIV nurse consultants*: M. Heitmuller, L. M. Laan. *HIV clinical virologists/chemists*: A. M. Pettersson, C. M. J. E. Vandenbroucke-Grauls, C. W. Ang. **Wilhelmina Kinderziekenhuis, University Medical Center Utrecht, Utrecht:** *HIV treating physicians*: S. P. M. Geelen, T. F. W. Wolfs, L. J. Bont. *HIV nurse consultants*: N. Nauta. **St. Elisabeth Hospitaal, Willemstad, Curaçao:** *HIV treating physicians*: C. Winkel, A. Durand, F. Muskiet, R. Voigt. *HIV nurse consultants*: I. van der Meer.

**Coordinating Center. Stichting HIV Monitoring:** *Director*: P. Reiss. *Data analysis*: D. O. Bezemer, L. Gras, A. I. van Sighem, C. Smit. *Data management and quality control*: S. Zaheri, M. Hillebregt, A. de Jong. *Data monitoring*: D. Bergsma, P. Hoekstra, A. de Lang, M. Berkhout, S. Grivell, A. Jansen, M. J. Rademaker, M. Raethke. *Data collection*: L. de Groot, M. van den Akker, Y. Bakker, M. Broekhoven, E. Claessen, A. El Berkaoui, E. Kruijne, C. Lodewijk, R. Meijering, L. Munjishvili, B. Peeck, C. Ree, R. Regtop, Y. Ruijs, M. Schoorl, S. Schnörr, E. Tuijn, L. Veenenberg, S. van der Vliet, T. Woudstra. *Patient registration*: B. Tuk.

cART

:   combination antiretroviral therapy

HPD

:   highest posterior density

IQR

:   interquartile range

MCMC

:   Markov chain Monte Carlo

MRCA

:   most recent common ancestor

MSM

:   men who have sex with men

pol

:   polymerase

PWID

:   persons who inject drugs

RR

:   risk ratio

[^1]: The authors have declared that no competing interests exist.

[^2]: Conceived and designed the experiments: DB AC CF. Performed the experiments: DB AC OR BED. Analyzed the data: DB AC. Contributed reagents/materials/analysis tools: AvS LG HSH NRF RvdH AJD PR FdW. Wrote the first draft of the manuscript: DB AC CF. Contributed to the writing of the manuscript: OR AvS HSH BED LG NRF RvdH AJD PR FdW. Enrolled patients: HSH AJD PR FdW. Agree with the manuscript's results and conclusions: DB AC OR AvS HSH BED LG NRF RvdH AJD PR FdW CF. All authors have read, and confirm that they meet, ICMJE criteria for authorship.

[^3]: ¶ Membership of the ATHENA observational cohort is provided in the Acknowledgments.
